Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Schaefer, Martin ^a,b   Sarkar, Rahul ^c   Diez Quevedo, Crisanto ^d  

^a KLINIKEN ESSEN MITTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Asklepios Westklinikum Hamburg   (Germany)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Depression; Hepatitis C; Interferon; Management; Psychiatric adverse events; Ribavirin

Indexed keywords

ALPHA INTERFERON; ILLICIT DRUG; RIBAVIRIN;

ALCOHOLISM; ANGER; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COMORBIDITY; COMPARATIVE STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; FATIGUE; HEALTH CARE MANAGEMENT; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HOSTILITY; HUMAN; IRRITABILITY; MANIA; MENTAL PATIENT; PREMEDICATION; PRIORITY JOURNAL; SLEEP DISORDER; SUICIDAL IDEATION;

DEPRESSION; HEPATITIS C; INTERFERON; MANAGEMENT; PSYCHIATRIC ADVERSE EVENTS; RIBAVIRIN;

HEPATITIS C; HUMANS; MENTAL DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84881014283     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit266     Document Type: Article

References (51)

1. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-82.
2. Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-90.
3. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
4. Bonner JE, Barritt AS, Fried MW, Evon DM. Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci 2012; 57: 1469-74.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
7. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005; 19(suppl 3): S13-9.
8. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIVinfected subjects. AIDS 2005; 19(suppl 3):S64-71.
9. Schafer A, Wittchen HU, Backmund M, et al. Psychopathological changes and quality of life in hepatitis C virus-infected, opioiddependent patients during maintenance therapy. Addiction 2009; 104: 630-40.
10. Zanini B, Covolo L, Donato F, Lanzini A. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 2010; 32: 2139-59.
11. Alavi M, Grebely J, Matthews GV, et al. Effect of pegylated interferonalpha- 2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 957-65.
12. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011; 18: 153-60.
13. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-52.
14. Nickel T, Sonntag A, Backmund M, Pollmacher T. Depression during therapy with interferon alpha - how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: 102-4.
15. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106: 977-84.
16. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
17. Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev 2008; 1: 177-87.
18. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99: 1167-75.
19. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40(suppl 5):S304-312.
20. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology, 2007; 46: 991-8.
21. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.
22. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
23. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-16.
24. Bonner JE, Barritt AS 4th, Fried MW, Evon DM. Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci 2012; 57: 1439-44.
25. Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-5.
26. Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs 2006; 66: 155-74.
27. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130: 226-38.
28. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
29. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol 2012; 32: 531-43.
30. Robaeys G, De Bie J, Wichers MC, et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.World J Gastroenterol 2007; 13: 5736-40.
31. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004; 45: 29-33.
32. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
33. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 522-8.
34. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.
35. Russo S, Boon JC, Korf J, Haagsma EB. Mirtazapine for the treatment of interferon-induced psychopathology. Gen Hosp Psychiatry 2003; 25:497.
36. Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5- HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1169-73.
37. Schaefer M, Winterer J, Sarkar R, et al. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disorders. Psychosomatics 2008; 49: 442-6.
38. Malek-Ahmadi P, Ghandour E. Bupropion for treatment of interferoninduced depression. Ann Pharmacother 2004; 38: 1202-5.
39. Martin KA, Krahn LE, Balan V, Rosati MJ. Modafinil's use in combating interferon-induced fatigue. Dig Dis Sci 2007; 52: 893-6.
40. Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18: 41-6.
41. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virusinfected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157: 94-103.
42. Neri S, Bertino G, Petralia A, et al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol 2010; 44: 210-7.
43. Ramsey SE, Engler PA, Stein MD, et al. Effect of CBT on depressive symptoms in methadone maintenance patients undergoing treatment for hepatitis C. J Addict Res Ther 2011; 2: 2-10.
44. Kraus MR, Schaffer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon induced depression. J Viral Hepat 2005; 12: 96-100.
45. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C - a pilot study. Dig Dis Sci 2007; 52: 2557-2563.
46. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferonalpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-8.
47. de Knegt RJ, Bezemer G, Van Gool AR, et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 1306-17.
48. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83-90.
49. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a doubleblind, placebo-controlled trial. Psychosomatics 2010; 51: 401-8.
50. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38: 338-45.
51. Schmidt F, Janssen G, Martin G, et al. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 1049-59.